资金持续加速布局港股创新药板块。Wind数据显示，截至7月6日，全市场规模最大的港股创新药ETF （513120）近1个月（6月9日~7月6日）累计获资金净流入29.28亿元，最新规模达140.98亿元，创历史 新高，成为全市场规模最早突破140亿元的创新药类ETF，也是目前全市场规模最大的创新药类ETF。 流动性方面，港股创新药ETF（513120）近1月日均成交额达76亿元，居同类产品首位，叠加T+0交易机 制，为资金高效配置提供便利。 市场人士指出，港股创新药板块兼具"稀缺性+高弹性"特征，叠加政策红利与估值低位，中长期配置价 值显著。作为全市场规模最大、流动性最佳的创新药主题ETF，港股创新药ETF（513120）及其场外联 接（联接A：019670，联接C：019671）紧密跟踪中证香港创新药指数，精准投资港股创新药产业，或 是投资者布局创新药产业机遇的高效工具。 | 港股创新药ETF | 跟踪港股创新药(CNY)指数 | | 513120 | | --- | --- | --- | --- | | | 今年该指数 | 市盈率PE(TTM) | 指数处于发布以 | | 指数聚焦香港市场中不超过50家 ...

Group 1 - The Hang Seng Index and Hang Seng Tech Index experienced fluctuations, with the Hang Seng Healthcare Index rising by 2.88% and the Hang Seng Healthcare Index ETF (159557) increasing by 2.82% with a turnover rate exceeding 3% [1] - Notable stocks in the healthcare sector included Federated Pharmaceutical, which rose over 8%, along with other companies like CSPC Pharmaceutical and Kangzheng Pharmaceutical also showing gains [1] - The upcoming American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3, 2025, is expected to showcase over 70 research results from Chinese pharmaceutical companies, highlighting innovative drug candidates with potential for best-in-class status [1] Group 2 - Citic Securities indicated a clear trend of performance and valuation recovery in the healthcare industry, with a focus on innovation-driven strategies and internationalization, as well as reforms in outpatient marketing models for the second half of the year [2] - The A-share pharmaceutical sector and Hong Kong's innovative drug sector are currently at five-year low positions, with public fund holdings in the pharmaceutical industry reaching their lowest point since Q2 2020 in Q4 2024, but showing signs of recovery in Q1 2025 [2] - The global pharmaceutical investment and financing scale has shifted from a downward trend to a low-level oscillation upwards, with many growth-oriented pharmaceutical companies currently having PEG levels below 1, indicating potential for performance and valuation improvements [2] Group 3 - China’s innovative drug licensing out (Lisence out) total amount is projected to exceed $50 billion in 2024, reaching $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total in similar transactions [3] - The record licensing amount for SSGJ-707 is expected to accelerate the trend of Chinese pharmaceutical companies expanding internationally, with a noticeable increase in the number and value of licensing out agreements in recent years [3]